SG10201703243QA - Inhalable pharmaceutical compositions - Google Patents
Inhalable pharmaceutical compositionsInfo
- Publication number
- SG10201703243QA SG10201703243QA SG10201703243QA SG10201703243QA SG10201703243QA SG 10201703243Q A SG10201703243Q A SG 10201703243QA SG 10201703243Q A SG10201703243Q A SG 10201703243QA SG 10201703243Q A SG10201703243Q A SG 10201703243QA SG 10201703243Q A SG10201703243Q A SG 10201703243QA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical compositions
- inhalable pharmaceutical
- inhalable
- compositions
- pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261604435P | 2012-02-28 | 2012-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201703243QA true SG10201703243QA (en) | 2017-06-29 |
Family
ID=48628732
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201405243TA SG11201405243TA (en) | 2012-02-28 | 2013-02-28 | Inhalable pharmaceutical compositions |
| SG10201703243QA SG10201703243QA (en) | 2012-02-28 | 2013-02-28 | Inhalable pharmaceutical compositions |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201405243TA SG11201405243TA (en) | 2012-02-28 | 2013-02-28 | Inhalable pharmaceutical compositions |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10022303B2 (en) |
| EP (1) | EP2819645A2 (en) |
| JP (1) | JP6231022B2 (en) |
| KR (2) | KR20200015828A (en) |
| CN (2) | CN104703584B (en) |
| AU (3) | AU2013227351B2 (en) |
| CA (1) | CA2865702C (en) |
| HK (1) | HK1252926A1 (en) |
| IL (1) | IL234365B (en) |
| NZ (2) | NZ722952A (en) |
| RU (2) | RU2697862C2 (en) |
| SG (2) | SG11201405243TA (en) |
| WO (1) | WO2013128283A2 (en) |
| ZA (1) | ZA201703992B (en) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4400921A3 (en) | 2012-06-25 | 2024-10-09 | Gecko Health Innovations, Inc. | Devices, systems, and methods for adherence monitoring and patient interaction |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757529B2 (en) * | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| JP2016518388A (en) | 2013-04-30 | 2016-06-23 | オティトピック インク． | Dry powder formulation and usage |
| PL3038687T3 (en) | 2013-08-28 | 2019-08-30 | Gecko Health Innovations, Inc. | Devices for adherence monitoring and devices for monitoring use of consumable dispensers |
| EP3104854B1 (en) | 2014-02-10 | 2020-04-08 | Respivant Sciences GmbH | Mast cell stabilizers for lung disease treatment |
| AU2015213678C1 (en) | 2014-02-10 | 2019-03-21 | Respivant Sciences Gmbh | Mast cell stabilizers treatment for systemic disorders |
| CA2977083A1 (en) | 2014-02-20 | 2015-08-27 | Kambiz Yadidi | Dry powder formulations for inhalation |
| JP6672258B2 (en) * | 2014-04-08 | 2020-03-25 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | Nicotine preparation and method for producing the same |
| CA2951063C (en) * | 2014-06-06 | 2022-10-04 | Merck Patent Gmbh | Antigen-loaded chitosan nanoparticles for immunotherapy |
| CN113406152B (en) | 2014-06-09 | 2024-09-20 | 生物统计股份有限公司 | Low cost test strip and method for measuring analytes |
| US11175268B2 (en) | 2014-06-09 | 2021-11-16 | Biometry Inc. | Mini point of care gas chromatographic test strip and method to measure analytes |
| CN107072947A (en) * | 2014-07-31 | 2017-08-18 | 奥迪托皮克股份有限公司 | dry powder formulation for inhalation |
| CA2965759C (en) | 2014-10-31 | 2023-12-12 | Glaxosmithkline Intellectual Property Development Limited | Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials |
| WO2016176552A1 (en) | 2015-04-30 | 2016-11-03 | Otitopic Inc. | Dry power formulations for inhalation |
| WO2016196401A1 (en) | 2015-05-29 | 2016-12-08 | The Texas A&M University System | Antimicrobial and anti-inflammatory compositions |
| ES2809482T3 (en) | 2015-06-30 | 2021-03-04 | Nestle Sa | Adequate composition to protect microorganisms |
| US10238625B2 (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| KR101880295B1 (en) * | 2016-01-12 | 2018-08-02 | 주식회사 시너지이노베이션 | Composition comprising dihydroergotamine tartrate for preventing or treating lung cancer |
| JP6323846B2 (en) * | 2016-04-07 | 2018-05-16 | 塩野義製薬株式会社 | Abuse prevention formulation containing opioid |
| WO2017192993A1 (en) | 2016-05-05 | 2017-11-09 | Liquidia Technologies, Inc. | Dry powder treprostinil for the treatment of pulmonary hypertension |
| CN109715067B (en) | 2016-07-19 | 2022-05-17 | 生物统计股份有限公司 | Method and system for measuring analytes using batch calibratable test strips |
| CA3035528A1 (en) | 2016-08-31 | 2018-03-08 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
| WO2018047002A1 (en) | 2016-09-12 | 2018-03-15 | St Ip Holding Ag | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same |
| WO2018047013A1 (en) | 2016-09-12 | 2018-03-15 | St Ip Holding Ag | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same |
| AU2017339366A1 (en) | 2016-10-07 | 2019-04-11 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of pulmonary fibrosis |
| US10786456B2 (en) * | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| KR102507987B1 (en) * | 2017-09-22 | 2023-03-21 | 벡추라 인코포레이티드 | Dry Powder Composition with Magnesium Stearate |
| EP3746080A4 (en) | 2018-02-01 | 2021-11-17 | Corvus Pharmaceuticals, Inc. | PHARMACEUTICAL FORMULATIONS |
| EP3749298B1 (en) | 2018-02-07 | 2023-04-05 | Lovelace Biomedical Research Institute | Inhalable dry powder cytidine analogue composition and method of use as a treatment for cancer |
| EP3762104A2 (en) | 2018-03-07 | 2021-01-13 | ST IP Holding AG | Combination compositions and therapies comprising 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, and methods of making and using same |
| IT201800006909A1 (en) * | 2018-07-04 | 2020-01-04 | DRY POWDER OF AMBROXOL FOR INHALATION USE WITH BRONCHIAL TARGET | |
| US11774363B2 (en) | 2018-08-07 | 2023-10-03 | Norton (Waterford) Limited | Application of raman spectroscopy for the manufacture of inhalation powders |
| CN113694068A (en) | 2018-09-18 | 2021-11-26 | St知识产权控股公司 | Rotamers of 4-alkyl-5-heteroaryl-3H-1, 2-dithiole-3-thiones |
| GB2578093B (en) * | 2018-10-09 | 2020-11-18 | Verona Pharma Plc | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| EP3673895A1 (en) * | 2018-12-28 | 2020-07-01 | Université Libre de Bruxelles | Dry powder inhalation formulation and its use for the therapeutic treatment of lungs |
| US11499904B2 (en) * | 2020-02-12 | 2022-11-15 | National Guard Health Affairs | In vitro dissolution test method for fluticasone propionate and other inhaled drugs |
| TW202200144A (en) | 2020-03-16 | 2022-01-01 | 瑞士商Ｓｔ知識產權控股公司 | Rotomeric isomers of 4-alkyl-5-heteroaryl-3h-1,2-dithiole-3-thiones |
| US11135220B1 (en) | 2020-04-08 | 2021-10-05 | St Ip Holding Ag | Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione |
| IL300652A (en) | 2020-08-14 | 2023-04-01 | Norton Waterford Ltd | An inhalable formulation of fluticasone propionate and albuterol sulfate |
| CN112023062A (en) * | 2020-09-18 | 2020-12-04 | 北京基因安科技有限公司 | Method for inhibiting allergic reactions using soluble IgE receptors |
| KR102488719B1 (en) * | 2020-12-03 | 2023-01-13 | 충북대학교 산학협력단 | Dry powder inhalation formulation containing selexipag and manufacturing method thereof |
| KR20230039894A (en) * | 2021-09-14 | 2023-03-22 | 한국유나이티드제약 주식회사 | Inhalable Pharmaceutical Composition Used For Preventing or Treating COVID-19 INFECTION DISEASE |
| WO2023105086A1 (en) * | 2021-12-10 | 2023-06-15 | Gudiminchi Rama Krishna | Use of glycosylated sugar alcohols |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| CN120322221A (en) * | 2022-06-21 | 2025-07-15 | 好利安科技有限公司 | Crystalline pharmaceutical composition containing sugar and lipid complex particles for inhalation and preparation method thereof |
| KR20250084912A (en) | 2022-07-04 | 2025-06-11 | 호비온 사이언티아 리미티드 | Dry powder inhaler pharmaceutical composition of coated crystalline dry powder for inhalation |
| TW202506117A (en) | 2023-06-26 | 2025-02-16 | 英商維羅納製藥Ｐｌｃ公司 | Particulate composition |
| KR20250112022A (en) * | 2024-01-16 | 2025-07-23 | 피투케이바이오 주식회사 | Inhalation composition of rivaroxaban |
| CN120549895B (en) * | 2025-05-24 | 2025-11-25 | 上海华茂药业有限公司 | An inhalable powder formulation based on sieved lactose and its preparation method |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1084994B (en) * | 1976-06-09 | 1985-05-28 | Funk Heporaut Kirsti | GASKET FOR SHAFTS, IN PARTICULAR IN MILLS WITH AGIOTER OR IN COLLOIDAL MILLS |
| US5500331A (en) | 1994-05-25 | 1996-03-19 | Eastman Kodak Company | Comminution with small particle milling media |
| US5478705A (en) | 1994-05-25 | 1995-12-26 | Eastman Kodak Company | Milling a compound useful in imaging elements using polymeric milling media |
| US5718388A (en) * | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
| DE4425255A1 (en) * | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulation for inhalation application |
| SE9603669D0 (en) * | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
| HUP0101608A2 (en) * | 1998-04-18 | 2002-03-28 | Glaxo Group Limited | Pharmaceutical aerosol formulation and process for its preparation |
| GB0012261D0 (en) * | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel process |
| EP1313451B1 (en) * | 2000-08-31 | 2009-03-11 | Jagotec AG | Milled particles |
| DK1920763T3 (en) * | 2000-11-30 | 2014-07-07 | Vectura Ltd | Pharmaceutical preparations for inhalation |
| EP1498116A1 (en) * | 2002-03-20 | 2005-01-19 | Hosokawa Micron Corporation | Method of manufacturing chemical-containing composite particles |
| GB0208609D0 (en) * | 2002-04-13 | 2002-05-22 | Glaxo Group Ltd | Compositions |
| GB0321607D0 (en) * | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| WO2005072702A2 (en) * | 2004-01-20 | 2005-08-11 | Alkermes Controlled Therapeutics, Inc. | Method for milling frozen microparticles |
| JO3102B1 (en) | 2004-03-17 | 2017-09-20 | Chiesi Framaceutici S P A | Pharmaceutical formulations for dry powder inhalers comprising a low- dosage strength active ingredient |
| EP2076242B8 (en) | 2006-07-27 | 2013-02-20 | Nektar Therapeutics | Aerosolizable formulation comprising insulin for pulmonary delivery |
| GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
| RU2577698C2 (en) | 2009-03-26 | 2016-03-20 | Пулмэтрикс, Инк. | Dry powder formulations and methods of treating pulmonary diseases |
| US20120160944A1 (en) * | 2009-04-24 | 2012-06-28 | Aaron Dodd | Method for the production of commercial nanoparticle and micro particle powders |
| AU2009100698B4 (en) | 2009-07-17 | 2010-04-15 | Astrazeneca Ab | Combination |
| PH12012501064B1 (en) * | 2009-12-14 | 2017-09-27 | Chiesi Farm Spa | Antibiotic microparticles for inhalation |
-
2013
- 2013-02-28 US US13/781,115 patent/US10022303B2/en not_active Expired - Fee Related
- 2013-02-28 CA CA2865702A patent/CA2865702C/en not_active Expired - Fee Related
- 2013-02-28 RU RU2014139046A patent/RU2697862C2/en not_active IP Right Cessation
- 2013-02-28 CN CN201380022443.4A patent/CN104703584B/en not_active Expired - Fee Related
- 2013-02-28 WO PCT/IB2013/000708 patent/WO2013128283A2/en not_active Ceased
- 2013-02-28 SG SG11201405243TA patent/SG11201405243TA/en unknown
- 2013-02-28 KR KR1020207003233A patent/KR20200015828A/en not_active Ceased
- 2013-02-28 NZ NZ722952A patent/NZ722952A/en not_active IP Right Cessation
- 2013-02-28 CN CN201711261255.3A patent/CN107875127A/en active Pending
- 2013-02-28 EP EP13729407.0A patent/EP2819645A2/en not_active Withdrawn
- 2013-02-28 AU AU2013227351A patent/AU2013227351B2/en not_active Ceased
- 2013-02-28 RU RU2019110128A patent/RU2019110128A/en not_active Application Discontinuation
- 2013-02-28 JP JP2014559312A patent/JP6231022B2/en not_active Expired - Fee Related
- 2013-02-28 SG SG10201703243QA patent/SG10201703243QA/en unknown
- 2013-02-28 KR KR1020147027464A patent/KR20150041608A/en not_active Ceased
- 2013-02-28 NZ NZ629438A patent/NZ629438A/en not_active IP Right Cessation
-
2014
- 2014-08-28 IL IL234365A patent/IL234365B/en active IP Right Grant
-
2015
- 2015-11-23 HK HK18112279.7A patent/HK1252926A1/en unknown
-
2016
- 2016-05-04 AU AU2016202881A patent/AU2016202881A1/en not_active Abandoned
-
2017
- 2017-06-09 ZA ZA2017/03992A patent/ZA201703992B/en unknown
- 2017-08-08 AU AU2017213466A patent/AU2017213466B2/en not_active Ceased
-
2018
- 2018-07-16 US US16/036,595 patent/US20180318170A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL234365B (en) | 2019-09-26 |
| US10022303B2 (en) | 2018-07-17 |
| AU2017213466B2 (en) | 2019-03-14 |
| JP6231022B2 (en) | 2017-11-15 |
| WO2013128283A2 (en) | 2013-09-06 |
| CN104703584B (en) | 2019-05-31 |
| CA2865702C (en) | 2020-04-28 |
| WO2013128283A3 (en) | 2013-10-31 |
| JP2015508808A (en) | 2015-03-23 |
| US20180318170A1 (en) | 2018-11-08 |
| RU2014139046A (en) | 2016-04-20 |
| AU2013227351A1 (en) | 2014-09-18 |
| CN107875127A (en) | 2018-04-06 |
| RU2019110128A3 (en) | 2020-06-04 |
| KR20150041608A (en) | 2015-04-16 |
| NZ722952A (en) | 2018-12-21 |
| NZ629438A (en) | 2016-10-28 |
| HK1252926A1 (en) | 2019-06-06 |
| AU2017213466A1 (en) | 2017-08-31 |
| RU2019110128A (en) | 2019-05-08 |
| KR20200015828A (en) | 2020-02-12 |
| EP2819645A2 (en) | 2015-01-07 |
| ZA201703992B (en) | 2019-12-18 |
| US20140065219A1 (en) | 2014-03-06 |
| HK1210706A1 (en) | 2016-05-06 |
| SG11201405243TA (en) | 2014-09-26 |
| CN104703584A (en) | 2015-06-10 |
| AU2013227351B2 (en) | 2016-06-16 |
| AU2016202881A1 (en) | 2016-05-26 |
| RU2697862C2 (en) | 2019-08-21 |
| CA2865702A1 (en) | 2013-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201703992B (en) | Inhalable pharmaceutical compositions | |
| IL230010B (en) | Inhalable pharmaceutical compositions | |
| IL234831A0 (en) | Pharmaceutical compositions for combination therapy | |
| GB201113662D0 (en) | Pharmaceutical compositions | |
| AP3656A (en) | Pharmaceutical compositions | |
| ZA201503594B (en) | Pharmaceutical compositions | |
| ZA201308208B (en) | Pharmaceutical compositions | |
| ZA201501930B (en) | Pharmaceutical composition | |
| EP2832730A4 (en) | Mirabegron-containing pharmaceutical composition | |
| SG11201403875VA (en) | Oral pharmaceutical composition | |
| IL266415A (en) | Novel pharmaceutical composition | |
| LT2814473T (en) | Pharmaceutical compositions for combination therapy | |
| IL237146A0 (en) | Pharmaceutical composition comprising rebamipide | |
| GB201118181D0 (en) | Pharmaceutical compositions | |
| ZA201502987B (en) | Pharmaceutical composition | |
| GB201211153D0 (en) | Pharmaceutical compositions | |
| IL238075A0 (en) | Pharmaceutical compositions | |
| GB201219234D0 (en) | Pharmaceutical compositions | |
| GB201213303D0 (en) | Pharmaceutical compositions | |
| GB201204810D0 (en) | Pharmaceutical compositions | |
| ZA201400751B (en) | Pharmaceutical composition | |
| GB201221130D0 (en) | New pharmaceutical composition | |
| GB201207701D0 (en) | New pharmaceutical composition | |
| GB201207628D0 (en) | New pharmaceutical composition | |
| HUE043019T2 (en) | Pharmaceutical compositions for combination therapy |